Keratose as a Novel Drug Carrier for Drug Coated Balloons

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Southern Biomedical Engineering Conference

• Publication date

  2016-03-11

• Fields of study

  Medicine, Materials Science

• Identifiers
  DOI 10.1109/SBEC.2016.33
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty.

  2014cited by this paper
• Hemostatic properties and the role of cell receptor recognition in human hair keratin protein hydrogels.

  2013cited by this paper
• Dose Response to Paclitaxel-Coated Balloon Catheters in the Porcine Coronary Overstretch and Stent Implantation Model

  2011cited by this paper
• Keratin hydrogels support the sustained release of bioactive ciprofloxacin.

  2011cited by this paper
• Mechanical and biological properties of keratose biomaterials.

  2011cited by this paper
• Some properties of keratin biomaterials: kerateines.

  2010cited by this paper
• Optimization of drug‐eluting balloon use for safety and efficacy: Evaluation of the 2nd generation paclitaxel‐eluting DIOR‐balloon in porcine coronary arteries

  2010cited by this paper
• Paclitaxel-coated balloon versus drug-eluting stent during PCI of small coronary vessels, a prospective randomised clinical trial. The PICCOLETO Study

  2010cited by this paper
• Paclitaxel Balloon Coating, a Novel Method for Prevention and Therapy of Restenosis

  2004cited by this paper
• Addition of paclitaxel to contrast media prevents restenosis after coronary stent implantation.

  2003cited by this paper

• Overview of Protein‐Based Biopolymers for Biomedical Application

  2019cites this paper